Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Unlabelled: Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia. However, access to in-person CBT-I remains limited due to a shortage of trained providers and structural barriers. Digital CBT-I (dCBT-I) offers a scalable solution to bridge this treatment gap, yet real-world evidence of its effectiveness remains limited. This study aims to examine the effectiveness of a mobile dCBT-I intervention, "SleepQ," in a routine clinical setting. This study is a multicenter, two-arm, open-label, randomized controlled trial comparing a mobile dCBT-I intervention to a waitlist control group. A total of 120 adults with chronic insomnia will be recruited from six clinics in South Korea. Participants will be randomly assigned (1:1) to either the intervention group receiving 6 weeks of dCBT-I or the control group, which will gain access to the intervention after the posttreatment assessment. The primary outcome is the Insomnia Severity Index score change from baseline to 6 weeks post-randomization. Secondary outcomes include dysfunctional sleep beliefs, daytime sleepiness, depressive and anxiety symptoms, quality of life, and work productivity. Exploratory outcomes include adherence, usability, app satisfaction, and sleep parameters from the integrated sleep diary. In the intervention group, follow-up assessments will be conducted 3- and 6-months post-randomization to evaluate long-term effects. This trial will evaluate the effectiveness of mobile dCBT-I for chronic insomnia within routine clinical care. Findings will contribute to the evaluation of the clinical implementation of digital therapeutics for insomnia and inform the integration of mobile-based CBT-I into routine care.

Clinical Trial Registration: https://clinicaltrials.gov/study/NCT06695000, ClinicalTrials.gov (NCT06695000).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240122PMC
http://dx.doi.org/10.1016/j.invent.2025.100848DOI Listing

Publication Analysis

Top Keywords

chronic insomnia
16
mobile dcbt-i
12
insomnia routine
8
randomized controlled
8
controlled trial
8
remains limited
8
effectiveness mobile
8
dcbt-i intervention
8
routine clinical
8
control group
8

Similar Publications

Background: Although opioid analgesics may influence sleep in patients with chronic pain, the association between strong opioid use and sleep characteristics remains unclear. This study aimed to explore differences in sleep status among chronic pain patients with varying levels of opioid use.

Methods: A total of 29 patients with chronic non-cancer pain who had been under treatment for more than 6 months were included.

View Article and Find Full Text PDF

[ acupuncture modulates Glu/GABA‑Gln metabolic loop abnormalities in insomniac rats].

Nan Fang Yi Ke Da Xue Xue Bao

August 2025

Department of Nursing, Shenzhen Hospital, Southern Medical University, Shenzhen 518101, China.

Objectives: To investigate the therapeutic effect of acupuncture in a rat model of insomnia and its regulatory effect on the glutamic acid (Glu)/γ-aminobutyric acid (GABA)-glutamine (Gln) metabolic loop.

Methods: Forty male SD rats were randomly assigned to control group, model group, group and group (=10). In the latter 3 groups, rat models of insomnia were established by intraperitoneal injections of p-chlorophenylalanine and verified using a sodium pentobarbital-induced sleep test.

View Article and Find Full Text PDF

Jiao-tai-wan and Its Bioactive Constituent Jatrorrhizine Exert Antidepressant Effects via the STING Pathway.

J Ethnopharmacol

September 2025

Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. Electronic address:

Ethnopharmacological Relevance: Jiao-tai-wan (JTW) is a classical traditional Chinese medicine formula that has long been used to treat insomnia. Recent pharmacological studies have highlighted its potential antidepressant effects. However, its role in regulating neuroinflammation associated with depression and the underlying mechanisms remains unclear.

View Article and Find Full Text PDF

Optimizing timing and dose of exogenous melatonin administration in neuropsychiatric pediatric populations: a meta-analysis on sleep outcomes.

Sleep Med Rev

August 2025

Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, Viale Del Tirreno. 341/A/B/C, Calambrone, Pisa, 56128 Italy; Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Via Savi 10, 56126, Pisa, Italy.

Melatonin is known to be effective in improving sleep in pediatric patients affected by neurological and psychiatric conditions. However, no guidelines exist advising the most effective treatment schedule. This systematic review and meta-analysis aimed to identify the dose, time of administration and treatment duration associated with the maximal treatment efficacy.

View Article and Find Full Text PDF

Pharmacological Management of Insomnia in Parkinson's Disease.

Sleep Med Clin

September 2025

Parkinson Foundation Centre of Excellence, King's College Hospital and King's College, London, United Kingdom; King's College Hospital, London, Dubai, UAE; Institute of Psychiatry, Psychology and Neuroscience, King's College, Dementech Clinical Neuroscience Centre London, United Kingdom. Electronic

Sleep dysfunction can affect almost 90% of Parkinson's disease (PD) patients and insomnia related to fragmented sleep is common. Satisfactory management remains an unmet need although dopaminergic non-oral treatments utilising a continuous drug delivery strategy appears to help sleep maintenance insomnia. Transdermal therapy with rotigotine or subcutaneous apomorphine infusion is effective while recent data show considerable efficacy of intrajejunal or subcutaneous levodopa infusion on alleviation of insomnia in PD.

View Article and Find Full Text PDF